Parallel workflows vital to gain regulatory approvals for AI in digital pathology

Must Read

Why cybersecurity threats have increased during Covid-19 pandemic

Cybersecurity industry has never had more significant task to carry out than guarding strategic associations and businesses from digital assaults during the coronavirus pandemic

How to choose an effective DDoS mitigation plan

There are several flavours from which to choose when selecting an effective DDoS mitigation strategy. Most enterprises opt for one of the cloud protection flavours (always-on or on-demand)

Ensuring brand protection against cyber attacks

Companies across all industries and sizes must make sure that they are protected and safeguarded against all forms of cyberattacks today

According to , over the next decade, there will be a shift in and artificial intelligence () applications from the pharmaceutical sector to clinical diagnostics. Once they are established as primary and secondary diagnostic tools, clinicians will be able to decrease turnaround time, prioritize critical cases, and improve overall patient outcomes. However, for AI tools to gain regulatory approval for primary diagnosis in digital pathology, it is imperative to adopt a parallel workflow to showcase the superior benefits of pathology diagnoses that amass data.

“AI has the potential to analyze big data and find patterns and insights that could enhance patient outcomes in the field of pathology,” said Frost & Sullivan Analyst. “It can serve as a supplementary or a validation tool in imaging analytics for pathologists, and help process more slides in a shorter duration.

“So far, AI-based medical diagnostic tools like OsteoDetect have already been approved for use by the FDA for the detection of distal radius fracture. Furthermore, AI-powered tools can better identify skin lesions and the presence of invasive breast cancer,” said Frost & Sullivan Analyst.

“Hospitals and diagnostic labs will be the largest adopters of digital pathology over the next decade,” said the analyst. “Technology innovators can ensure greater commercialization by focusing on improving cost optimization for end users through pay-per-use or Software-as-a-Service (SaaS) models,” said Frost & Sullivan Analyst.

“Additionally, they could map service gaps, expand product portfolios, and use the information obtained from clinical data to develop cutting-edge solutions,” said Frost & Sullivan Analyst.

Subscribe to receive the day's headlines from Tech Observer straight in your inbox

Leave a Reply

*The moderation of comments is automated and not cleared manually by techobserver.in. Embedding of any link and use of abusive or unparliamentary language are prohibited.
- Advertisement -

Latest in TECH

Related Articles